Loading
A phase 3 trial of Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell） in advanced solid tumours, run by Sinocelltech Ltd., active and no longer recruiting.
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years is a phase 3 interventional study registered as NCT06041061 by Sinocelltech Ltd., with 18000 participants enrolled, started 2023-08-13 and due to reach its primary completion in 2024-03. Interventions recorded: Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell） and placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sinocelltech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sinocelltech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/